Get the Stockscreener App
123.93
0.09%
0.11
After Hours:
123.98
0.05
+0.04%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Merck Co Inc stock is traded at $123.93, with a volume of 8.45M.
It is up +0.09% in the last 24 hours and up +14.56% over the past month.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
See More
Previous Close:
$123.82
Open:
$123.41
24h Volume:
8.45M
Relative Volume:
0.60
Market Cap:
$307.60B
Revenue:
$65.00B
Net Income/Loss:
$18.26B
P/E Ratio:
17.03
EPS:
7.2751
Net Cash Flow:
$13.05B
1W Performance:
+1.94%
1M Performance:
+14.56%
6M Performance:
+41.85%
1Y Performance:
+35.78%
1-Day Range:
$122.63
$124.84
1-Week Range:
$120.39
$124.84
52-Week Range:
$73.31
$124.84
Merck Co Inc Stock (MRK) Company Profile
Name
Merck Co Inc
Sector
Industry
Phone
908-740-4000
Address
126 EAST LINCOLN AVENUE, RAHWAY, NJ
Compare MRK vs LLY, JNJ, ABBV, AZN, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
123.93 | 307.32B | 65.00B | 18.26B | 13.05B | 7.2751 |
|
LLY
Lilly Eli Co
|
1,042.15 | 998.60B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
246.28 | 592.45B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
228.44 | 405.58B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
AZN
Astrazeneca Plc
|
206.61 | 317.72B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
167.11 | 314.27B | 54.72B | 14.02B | 15.32B | 7.1855 |
Merck Co Inc Stock (MRK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-13-26 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-08-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-18-25 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Nov-24-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Oct-13-25 | Resumed | Citigroup | Neutral |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Feb-18-25 | Downgrade | Deutsche Bank | Buy → Hold |
| Feb-10-25 | Downgrade | TD Cowen | Buy → Hold |
| Jan-08-25 | Downgrade | Truist | Buy → Hold |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Dec-04-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-11-24 | Downgrade | Daiwa Securities | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Mar-11-24 | Downgrade | Societe Generale | Hold → Sell |
| Jan-04-24 | Upgrade | TD Cowen | Market Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Buy |
| Oct-27-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Oct-20-23 | Upgrade | UBS | Neutral → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Hold |
| Apr-13-23 | Upgrade | Citigroup | Neutral → Buy |
| Mar-28-23 | Downgrade | Societe Generale | Buy → Hold |
| Mar-13-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-06-23 | Initiated | Jefferies | Buy |
| Feb-22-23 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-04-23 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Oct-10-22 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-14-22 | Upgrade | Berenberg | Hold → Buy |
| Jul-06-22 | Upgrade | Daiwa Securities | Neutral → Buy |
| Jun-06-22 | Resumed | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-16-21 | Initiated | Daiwa Securities | Neutral |
| Dec-13-21 | Downgrade | UBS | Buy → Neutral |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Dec-07-21 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-29-21 | Downgrade | Citigroup | Buy → Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-01-21 | Upgrade | Argus | Hold → Buy |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-27-21 | Resumed | Truist | Buy |
| May-20-21 | Downgrade | Argus | Buy → Hold |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Aug-03-20 | Upgrade | Goldman | Neutral → Buy |
| Jun-12-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-16-19 | Initiated | SVB Leerink | Outperform |
| Jul-03-19 | Initiated | Mizuho | Buy |
| May-28-19 | Initiated | Goldman | Neutral |
| May-13-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-16-18 | Reiterated | Citigroup | Buy |
| Oct-09-18 | Resumed | Guggenheim | Buy |
| Apr-23-18 | Upgrade | Goldman | Neutral → Buy |
| Apr-17-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-05-18 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-12-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Feb-14-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-07-18 | Reiterated | Morgan Stanley | Equal-Weight |
| Jan-16-18 | Upgrade | SunTrust | Hold → Buy |
View All
Merck Co Inc Stock (MRK) Latest News
How Is Merck & Co.'s Stock Performance Compared to Other Healthcare Stocks? - Yahoo Finance
Merck to Participate in the TD Cowen 46th Annual Health Care Conference - PharmiWeb.com
Amazon, Merck, PG&E And More On CNBC's 'Final Trades' - Benzinga
First American Trust FSB Acquires 12,478 Shares of Merck & Co., Inc. $MRK - MarketBeat
Mufg Securities Americas Inc. Grows Stake in Merck & Co., Inc. $MRK - MarketBeat
First Financial Bankshares Inc Boosts Holdings in Merck & Co., Inc. $MRK - MarketBeat
Merck Animal Health Receives S&P Global Awards for NUMELVI® and INNOVAX® ND-ILT-IBD - global-agriculture.com
Merck (MRK) Announces Positive Phase 3 SMART Trial Results for ENFLONSIA (Clesrovimab) - Finviz
Merck & Co to spin off cancer unit ahead of Keytruda patent cliff - Sharecast.com
Merck (NYSE:MRK) Hits Annual High in Russell 1000 - Kalkine Media
1 Reason I'd Buy Veeva Systems Stock and Never Sell - The Motley Fool
Merck & Co., Inc. (NYSE:MRK) Hits New 52-Week HighTime to Buy? - MarketBeat
Merck & Company, Inc. (MRK) Stock Analysis: Analyst Ratings Signal Strong Buy Potential Amidst Robust Growth - DirectorsTalk Interviews
Barclays Highlights Merck's (MRK) Pipeline Catalysts in Coverage Initiation - Finviz
Barclays Highlights Merck’s (MRK) Pipeline Catalysts in Coverage Initiation - Insider Monkey
Merck to Create a Separate Cancer Unit as Patent Cliff Looms - Bloomberg
Merck's strategic shift signals new growth horizons - MSN
Merck's Strategic Shift Signals New Growth Horizons - Benzinga
Merck reportedly ready to the splits as Keytruda patent cliff looms. Market shrugs - Proactive Investors
Merck to split human health unit into two divisions (MRK:NYSE) - Seeking Alpha
Payden & Rygel Grows Stock Holdings in Merck & Co., Inc. $MRK - MarketBeat
Merck Evolves Human Health Operating Structure to Support Portfolio Execution - Business Wire
Merck & Co., Inc. $MRK Shares Sold by Kovitz Investment Group Partners LLC - MarketBeat
Merck & Co., Inc. (NYSE:MRK) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
How Merck Is Using 3D Printing To Create Innovative Solutions - CSRwire
Westerkirk Capital Inc. Grows Holdings in Merck & Co., Inc. $MRK - MarketBeat
Merck: Why Investors Should Remain Bullish Despite Patent Risks - Seeking Alpha
Lansforsakringar Fondforvaltning AB publ Boosts Holdings in Merck & Co., Inc. $MRK - MarketBeat
Hillsdale Investment Management Inc. Cuts Position in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Stock Holdings Lifted by EDENTREE ASSET MANAGEMENT Ltd - MarketBeat
Smead Capital Management Inc. Has $254.70 Million Holdings in Merck & Co., Inc. $MRK - MarketBeat
Tredje AP fonden Boosts Holdings in Merck & Co., Inc. $MRK - MarketBeat
Barclays Upgrades Merck & Co., Inc. (NYSE:MRK) to Strong-Buy - MarketBeat
Merck & Co., Inc. $MRK Shares Sold by ANTIPODES PARTNERS Ltd - MarketBeat
AMG National Trust Bank Acquires 45,996 Shares of Merck & Co., Inc. $MRK - MarketBeat
Deutsche Bank Upgrades Merck (MRK) to Buy, Sees "Clear Path" Beyond Keytruda Patent Cliff - Finviz
Deutsche Bank Upgrades Merck (MRK) to Buy, Sees “Clear Path” Beyond Keytruda Patent Cliff - Insider Monkey
Merck vs. Bristol Myers: Which Pharma Stock Is a Better Pick in 2026? - Finviz
Merck & Co. (MRK) advances on robust Keytruda sales and positive clinical trial results - MSN
Merck & Co., Inc. (NYSE:MRK) Now Covered by Analysts at Barclays - MarketBeat
Merck & Co., Inc. $MRK Shares Acquired by ICICI Prudential Asset Management Co Ltd - MarketBeat
Here Are Friday’s Top Wall Street Analyst Research Calls: Amgen, ETSY, Eldorado Gold, GE Aerospace, Merck, Southern Company, Walmart, Yeti, and More - 24/7 Wall St.
NewEdge Wealth LLC Boosts Stake in Merck & Co., Inc. $MRK - MarketBeat
29,451 Shares in Merck & Co., Inc. $MRK Bought by CenterBook Partners LP - MarketBeat
MRK Stock Price, Forecast & Analysis | MERCK & CO. INC. (NYSE:MRK) - ChartMill
Where is Merck & Co., Inc. (MRK) Headed According to the Street? - Finviz
Merck posts new Enflonsia RSV data in infants (MRK:NYSE) - Seeking Alpha
King Luther Capital Management Corp Sells 263,609 Shares of Merck & Co., Inc. $MRK - MarketBeat
Burling Wealth Partners LLC Sells 9,333 Shares of Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Shares Sold by Prospector Partners LLC - MarketBeat
First National Bank of Omaha Makes New Investment in Merck & Co., Inc. $MRK - MarketBeat
Merck Co Inc Stock (MRK) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.46%
0.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):